Jim Wells
Founder
EpiBiologics
10/10Traction
EpiBiologics develops bispecific antibodies using its EpiTAC platform to selectively degrade disease-causing extracellular proteins, targeting the 40% of the proteome that intracellular methods overlook. This approach aims to enhance therapeutic efficacy for cancer and autoimmune disorders while minimizing damage to healthy tissues.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$73MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Digitalis VenturesNo round attributed
- digitalisventures.com (opens in a new tab)investor website
Mission BioCapitalNo round attributed
- missionbiocapital.com (opens in a new tab)investor website
Funding rounds are not available yet.
Founders
Product
Problem
Existing intracellular protein degradation methods are unable to target the 40% of the proteome consisting of extracellular proteins, limiting therapeutic options for diseases caused by these proteins. Current treatments may also lack tissue selectivity, leading to off-target effects and damage to healthy tissues.
Solution
EpiBiologics is developing bispecific antibodies using its EpiTAC platform to selectively degrade disease-causing extracellular proteins. The EpiTAC platform utilizes a novel atlas of over 270 degradation-inducing protein receptors expressed on the surface of distinct tissue and cell types to create tissue-selective therapies against membrane and extracellular proteins. By directing protein degradation to specific tissues, EpiBiologics aims to enhance therapeutic efficacy while minimizing damage to healthy tissues. This approach offers a new therapeutic modality that removes the entire disease-causing protein and associated scaffolding to drive deep and long-lasting therapeutic responses.
Target Audience
The primary target audience includes patients with cancer, autoimmune disorders, and other serious diseases treatable through targeted extracellular protein degradation.
Features
- EpiTAC platform leverages a novel atlas of 270+ degradation-inducing protein receptors.
- Bispecific antibodies designed for selective degradation of extracellular proteins.
- Tissue-selective therapies target membrane and extracellular proteins.
- Aims to degrade the entire disease-causing protein and associated scaffolding.